Oxford BioDynamics Plc has released its 2023 Annual Report, which is now available in electronic form on its website. The report includes the Notice of Annual General Meeting and will be posted to shareholders shortly. The Annual General Meeting is scheduled to be held on 27 March 2024 at the company's UK office.
The company, known for developing precision medicine tests based on the EpiSwitch® 3D genomics platform, has two flagship products: EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. These tests have been launched in various countries and have significantly impacted the field of personalized healthcare.
Oxford BioDynamics has also launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test), and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. The company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which has been used to build molecular diagnostic classifiers for various medical purposes.
The company has engaged in numerous partnerships with big pharma and leading institutions, showcasing the widespread recognition and adoption of its technology. Oxford BioDynamics has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
Headquartered in Oxford, UK, and listed on AIM of the London Stock Exchange, Oxford BioDynamics also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia. The company's global presence and innovative products position it as a key player in the field of precision medicine and personalized healthcare.